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Background: 11ß–hydroxysteroid dehydrogenase type1 (11β-HSD1) converts inactive glucocorticoids to active
glucocorticoids which, in excess, leads to development of the various risk factors of the metabolic syndrome.
Recent studies clearly suggest that both increased expression and activity of 11β-HSD1 in metabolically active tissues
such as liver, muscle and adipose are implicated in tissue specific dysregulation which collectively contribute to the
whole body pathology seen in metabolic syndrome. In the present study we have evaluated CNX-010-49, a highly
potent, selective and ‘pan tissue’ acting 11β-HSD1 inhibitor, for its potential to modulate multiple risk factors of
the metabolic syndrome.
Methods: Male C57B6/J mice on high fat diet (DIO mice) were orally dosed with CNX-010-49 (30 mg/kg twice
daily; n = 8) or vehicle for 10 weeks. Fasting glucose, triglycerides, glycerol, free fatty acids, body weight and feed
intake were measured at selected time points. At the end of the treatment an OGTT and subsequently organ
histology was performed. In vitro, CNX-010-49 was evaluated in 3T3-L1 preadipocytes to assess impact on
adipocytes differentiation, hypertrophy and lipolysis whereas in fully differentiated C2C12 cells and in primary
mouse hepatocytes to assess the impact on glucose metabolism and hepatic glucose output respectively.
Results: CNX-010-49 a highly potent and selective pan tissue acting 11β-HSD1 inhibitor (EC50 = 6 nM) significantly
inhibits glucocorticoids and isoproterenol mediated lipolysis in mature 3T3-L1 adipocytes, improves muscle
glucose oxidation, reduces proteolysis and enhances mitochondrial biogenesis. Also a significant inhibition of
gluconeogenesis in primary mouse hepatocytes was observed. The treatment with CNX-010-49 resulted in a
significant decrease in fasting glucose, improved insulin sensitivity and glucose tolerance. Treatment also resulted
in a significant decrease in serum triglycerides levels and a complete inhibition of body weight gain without
affecting feed consumption. A significant reduction in the serum biomarkers like Plasminogen activator inhibitor-1
(PAI-1), interleukin 6 (IL-6) and Fetuin-A with CNX-010-49 treatment was observed indicating a potential to modulate
processes implicated in cardiovascular benefits.
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Conclusions: These results indicate that inhibition of 11β-HSD1 with CNX-010-49 can give a potential benefit in the
management of metabolic dysregulations that are seen in type 2 diabetes.
Keywords: 11β-HSD1, CNX-010-49, Glucose, Insulin sensitivity, Triglycerides, Adipogenesis and Body weight,
Type 2 Diabetes, Cardiovascular risksBackground
Glucocorticoids (GCs) play a critical role in multiple
metabolic processes, including glucose homeostasis, in-
sulin sensitivity and lipid metabolism. Also it is well
established that elevated glucocorticoid levels is linked
with increased cardiovascular events [1]. Metabolic syn-
drome and Cushing’s syndrome have some similar phe-
notypes that include hyperglycemia, visceral obesity,
dyslipidemia and insulin resistance [2].
There are two isoforms of 11β-Hydroxysteroid dehydro-
genase. 11β-HSD1 which converts the inactive 11β-keto
form (cortisone in humans and 11-dehydrocorticosterone
in rodents) to the active 11β-hydroxylated GCs (cortisol in
human and corticosterone in mice) [3]. It is expressed
primarily in GC target tissues such as liver, skeletal
muscle, adipose tissue and in the central nervous system
where it amplifies local GC action [4]. 11βHSD2 is
highly expressed in classical aldosterone-selective target
tissues, such as kidney [5] and prevents the inappropri-
ate activation of mineralocorticoid receptors by cortisol.
In conditions of excess NADPH, as seen in metabolic
overload; 11β-HSD1 functions as a reductase and gener-
ates active cortisol while in situations of low levels of
NADPH it functions as a dehydrogenase and generates
inactive cortisone [6]. In humans, in vivo dehydrogenase
activity of 11β-HSD1 has been demonstrated [7].
Animals administered GCs show similar dysregulation
in phenotype as seen in metabolic syndrome or T2DM
where they observed increased fasting hyperglycemia,
hyperinsulinemia and impaired β-cell response to oral glu-
cose challenge. These animals have shown hepatic steato-
sis and increased ectopic lipid accumulation in muscle [8].
In adipocytes GCs increase lipolysis and hypertrophy in
mature adipocytes [9] whereas in muscle GCs can in-
crease proteolysis and insulin resistance. In another study,
infusion of GCs has also shown in addition to the above
observations hyperleptinemia, hypertriglyceridemia, sig-
nificant decrease in uncoupling protein (UCP)-1 and
UCP-3 expression [10]. The loss of UCP1 expression is
shown to be attendant with decrease in non-shivering
thermogenesis [11,12].
In metabolic syndrome, the pathology is due to en-
hanced tissue level glucocorticoids [13]. Targeted disrup-
tion of the 11β-HSD1 leads to improvement in glucose
tolerance, improved lipid profile along with decreased glu-
coneogenic response [14]. Mice over expressing adipose11β-HSD1 develop visceral obesity which is further exac-
erbated by feeding high fat diet. These mice later devel-
oped all the phenotypes of metabolic syndrome including
hypertension [15,16].
11β-HSD1 expression and activity are significantly in-
creased in both skeletal muscle and fat tissue from
obese type 2 diabetes (T2DM) patients and also in
rodent models of disease suggesting a role for local glu-
cocorticoids re-amplification in the development of
obesity and the metabolic syndrome [13,17-20]. Also in-
creased 11β-HSD1 expression and activation in liver
and adipose has demonstrated a clear link between its
roles to T2DM as seen with glucose intolerance, in-
creased insulin resistance, increased adiposity and body
weight gain [21,22]. The concomitant increase in gluco-
corticoids in adipose leads to decreased adiponectin
levels, increased TNFα and fasting glucose whereas hep-
atic overexpression increased insulinemia, LDL cholesterol
and serum glucose levels. One study established the asso-
ciation impaired insulin signaling and 11β-HSD1 ex-
pression/activity in skeletal muscle where dexamethasone
treated myotubes showed reduced IRS1 expression, in-
creased Ser307 phosphorylation of IRS1 and reduced
downstream pSer473 Akt/PKB [23].
Pharmacological inhibition of 11β-HSD1 in different
rodent models has demonstrated an improvement in
glucose tolerance, insulin sensitivity as well as reduced
body weight gain [24-30]. Also 11β-HSD1 inhibition re-
duced serum triglycerides, cholesterol and frees fatty
acids levels. Importantly, inhibition of 11β-HSD1 re-
duces plaque progression and aortic cholesterol accumu-
lation murine model of atherosclerosis.
To date a few small molecule inhibitors of 11β-HSD1
have entered clinical studies. INCB13739 displayed sta-
tistically significant reductions in HbA1c and glucose in
T2DM patients where metformin monotherapy was in-
adequate [31]. MK-0916 decreased both blood pressure
and body weight with a trend to reduce waist circumfer-
ence and had no significant effect on blood glucose [32].
So far none of these interventions provided significant
overall protection from metabolic syndrome. One can
attribute this lack efficacy of 11β-HSD1 inhibitors may
be due to potential reversibility of the 11β-HSD1 enzym-
atic reaction. Selection of 11β-HSD1 inhibitors which in-
hibit reductase activity than dehydrogenase activity and
getting maximum inhibition in skeletal muscle apart
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a need for intervention that alters 11β-HSD1 enzyme ac-
tivity and thereby provides a significant benefit in the
management of metabolic syndrome.
Our understanding of 11β-HSD1 biology linking to
metabolic syndrome suggests that inhibition of 11β-HSD1
with highly potent compound in all the metabolically ac-
tive tissues like adipose, skeletal muscle and liver, will pro-
vide a complete benefit in controlling the disease. Also we
screened and selected the compounds that have shown
more inhibition of reductase activity than dehydrogenase
activity along with good tissue distribution and inhibition
in the above mentioned tissues. In this study, we have
evaluated CNX-010-49 (MW= 408.5), a highly potent and
selective 11β-HSD1 inhibitor for its potential to control
multiple facets of metabolic syndrome.
Methods
Cell culture and treatment
C2C12 cells (Mouse myoblasts, ATCC) were maintained
in 24-well plates (3X104 cells/well) at 37°C in DMEM
(Dulbecco’s modified Eagle’s medium) containing 25 mM
glucose and 10% FBS. When cells reached confluence, the
media was supplemented with 25 mM Glucose and 2% FBS
for myotubes formation. After 4 days of differentiation and
myotubes formation, cells were treated with media contain-
ing GPCI (25 mM glucose, 500 μM palmitate, 500 nM cor-
tisone, 10 ng/ml of TNFα, IL-1β & IFγ) with or without
1 μM of CNX-010-49 for 18 h. Post 18 h, cells were frozen
in TRIZOL (Sigma, USA) for further analysis.
3T3-L1 cells (Mouse embryonic fibroblast, ATCC) were
cultured in DMEM supplemented with 10% bovine calf
serum and 25 mM glucose. To induce the differentiation
of 3T3-L1 preadipocytes, two days of post-confluence
cells were treated with complete differentiated media
(CDM) which contains 100 nM insulin, 400 nM corti-
sone or 1 μM dexamethasone, 500 μM IBMX (isobutyl-
methylxanthine) with or without 1 μM of CNX-010-49.
Media was changed for every 2 days with fresh media
containing 100 nM insulin and CNX-010-49 till day 6.
On day 7 cells were cultured in regular culture media
and after 24 h, triglyceride content of the cells were esti-
mated (Diagnostic systems, Germany). One set of cells
were processed for Oil red O staining. Treated cells were
washed twice with phosphate-buffered saline (PBS), fixed
in 10% formalin for 1 h and washed once with 60% iso-
propanol. Cells were then stained with 60% of filtered oil
red O stock solution (0.35 g of oil red O (Sigma, USA)
in 100 ml of 100% isopropanol) for 15 min. Cells were
washed thrice with water for 5 min each and later visu-
alized under microscope.
For the measurement of adipocytes hypertrophy, mature
adipocytes were treated with media containing GPCI
(25 mM glucose, 500 μM palmitate, 500 nM cortisone,10 ng/ml of TNFα, IL-1β & IFγ) with or without 1 μM of
CNX-010-49 for 48 h. Post 48 h, cells were lysed and tri-
glyceride content of the cells was estimated (Diagnostics
system, Germany).
For lipolysis assay, fully differentiated 3T3-L1 cells
(mature adipocytes) were treated with 1 μM of iso-
proterenol and 100 nM cortisone with or without 1 μM
CNX-010-49 for 18 h. Glycerol released in the medium
was assayed using Free Glycerol Reagent (Sigma, USA).
Lipolysis data was normalized to total protein.Isolation, culturing and hepatic glucose release in primary
hepatocytes
Hepatocytes from Swiss albino mice were prepared as
per the method of Seglen [33]. Hepatocytes were col-
lected by centrifugation at 300 rpm for 3 min at 4°C.
The viability of the hepatocytes was measured by Trypan
blue exclusion and then seeded onto collagen coated 6
well/96-well tissue culture plates in DMEM containing
20% FBS and 10 mM Nicotinamide and maintained at
37°C in a humidified atmosphere of 5% CO2. After 3 h
of attachment, the medium was replaced with fresh
growth medium.
To measure glucose release from the hepatocytes, cells
were treated with gluconeogenesis inducing media (glu-
cose free DMEM media with 5 mM lactate, 5 mM pyru-
vate, 1 μM cortisone, 10 μM forskolin, 1% FBS with or
without 1 μM of CNX-010-49) for 18 h. Glucose re-
leased in the media was measured using GOD method
(Diagnostic systems, Germany). Values were normalized
to total protein. Also one set of treatment was processed
for gene expression analysis.11β-HSD1 cell-based enzymatic activity assay
CHO-K1 (ATCC) cells stably expressing human 11β-
HSD1 gene (OriGene Technologies, USA) and fully dif-
ferentiated subcutaneous human adipocytes (Zen-Bio,
Inc, USA) were used for determination of half-maximum
inhibitory concentration (IC50) of CNX-010-49 towards
human 11β-HSD1 isoform. Fully differentiated C2C12
cells (expressing native 11β-HSD1 protein) were used to
determine IC50 towards the mouse isoform.
For determination of IC50, CHO-K1 cells were seeded
in a serum free Ham’s F-12 media containing 400 nM cor-
tisone and 500 μM NADPH with or without CNX-010-49.
Inhibitor was dissolved in DMSO and diluted in media
serially to get different concentration to determine IC50
(8 concentrations were used starting from 0.001 nM to
3 μM). Post 18 h treatment, the culture media was ana-
lyzed for the inhibition of cortisone to cortisol conversion
using LCMS/MS (ABI-4000 QTRAP). Similar protocol
was followed with C2C12 cells to determine IC50 (from 1
nM to 3 μM) for mouse isoform.
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CHO-K1 cells transiently expressing human 11β-HSD2
and 17β-HSD3 gene (OriGene Technologies, USA) and
T47D (ATCC) breast cancer cell line that expresses 17β-
HSD1 were used to determine inhibitory constants to-
wards the respective enzymes.
For determination of inhibition towards HSD–related
enzymes; cortisol was used as substrate for 11β-HSD2
(which will be converted to cortisone), androstenedione
for 17β-HSD3 (converted to testosterone) and estrone
for 17β-HSD1 (converted to estradiol). Post 18 h of
treatment, the culture media was analyzed and inhibition
of respective substrate conversion was analyzed using
LCMS/MS (ABI-4000 QTRAP).
11β-HSD1 reductase and dehydrogenase enzymatic assay
N-terminal deleted human 11β-HSD1 pure protein
(cloned, expressed using pET27b vector in bacteria and
later purified in-house using Ni-NTA agarose beads) was
used to evaluate both reductase and dehydrogenase en-
zymatic activity. For reductase activity, the reaction buf-
fer contained 200 nM cortisone and 500 μM NADPH.
For dehydrogenase activity, the reaction buffer contain
200 nM cortisol and 500 μM NADP. After 4 h incuba-
tion at 37°C, converted cortisol or cortisone was ana-
lyzed using LCMS/MS (ABI-4000 QTRAP).
In vivo efficacy studies in C57BL/6j mice on high fat diet
Six week old male C57BL/6 J mice were housed 2 per
polypropylene cage, maintained at 23 ± 1°C, 60 ± 10%
humidity, exposed to 12 h cycles of light and dark. Con-
trol group (n =8) animals were fed a standard chow diet
(D10001; 10% kcal from fat); HFD (high fat diet) group
(n = 16) fed high fat diet (D12492; 60% kcal from
Research Diets, Inc., New Jersey, USA). After 11 weeks
of diet intervention, the HFD fed animals were random-
ized to either vehicle (HFD control) or CNX-01-49
(30 mg/kg, orally twice a day in 0.5% Carboxy methyl
cellulose) treatment groups (n = 8) based upon body
weight, glucose AUC during OGTT and fasting blood
glucose. The treatment was further continued for an-
other 10 weeks. Body weight, glucose in fasting (6 h)
and fed state, triglycerides in fasting (12 h) state were
measured weekly and plasma insulin was measured at
the end of study. At the end of the study, blood was col-
lected for determination of plasma glycerol and leptin
levels following which the mice were euthanized under
isoflurane anaesthesia and necropsied. Adipose tissues
were weighed and a portion was immediately collected
in formalin and processed for histological examination.
Animal experiment protocols and experimental procedures
were approved by the Connexios Institutional Animal
Ethics Committee which is in accordance with the AR-
RIVE guidelines (Additional file 1) [34].Quantitative PCR analysis
At the end of treatment periods, total RNA was extracted
from different tissues using TRIZOL. Equal amount of
RNA was reverse transcribed and later amplified using
specific primers. Beta-actin was used as an internal con-
trol for the quantitative analysis. The primer sequence is
available upon request.
DNA isolation and quantitative real-time PCR assay for
mitochondrial copy number
DNA from C2C12 myotubes was isolated using Phenol
extraction method. Quantitative real-time PCR was per-
formed for mtND1 (mitochondrial gene) using DNA as
template and normalized to HPRT (nuclear gene) gene.
Blood and plasma assay
Blood glucose was measured using hand-held Accu-
check glucometer (Roche Diagnostics, Germany). An
ultra-sensitive insulin enzyme-linked immunosorb-
ent assay (ELISA) kit (Downers Grove, USA) was
used to determine plasma insulin levels. Circulating
serum TG, plasma glycerol and leptin were estimated
using the TG estimation kit (Diagnostic systems,
Germany), glycerol estimation kit (Sigma, USA) and
Leptin estimation kit (R & D systems, USA) respect-
ively as per the manufacturer ’s instruction.
Ex vivo 11β-HSD1 inhibition assay
The duration and percent inhibition of 11β-HSD1 activity
by CNX-010-49 (30 mg/kg, single dose orally) in different
tissues (liver, adipose, skeletal muscle and brain) in Swiss
albino mice was evaluated by an ex vivo 11β-HSD1 inhib-
ition assay. We have used 4 animals for every time point
in the study. After dosing the animals orally, animals were
sacrificed at each time point and different tissues (liver,
skeletal muscle, adipose and brain) were removed, minced
and incubated with cortisone for 16 h. Converted cortisol
was measured by LCMS/MS (ABI-4000 QTRAP) and the
percent inhibition of 11β-HSD1 activity relative to
vehicle-treated controls was calculated.
Oral Glucose Tolerance Test (OGTT)
After a 6 h fast, CNX-010-49 or vehicle was administered
60 min prior to administration of glucose (2 g/kg body wt)
by oral gavage. Blood samples were collected from the tail
vein 60 min before treatment and at 0, 10, 20, 30, 60, 90
and 120 min after glucose load for estimating glucose.
Insulin tolerance test (ITT)
ITT was performed in 6 h fasted mice during 9th week
of treatment. Blood samples were collected prior to and
at 0, 15, 30 and 60 min after insulin (human R Insulin,
Eli Lilly) administration (2 IU/kg, i.p.) for glucose
estimation.
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Pyruvate Tolerance Test (PTT) was performed in over-
night fasted mice during 10th week of treatment. Blood
samples were collected from the tail vein 60 min before
treatment and at 0, 15, 30, 60, 90 and 120 min after
pyruvate load (2 g/kg, intraperitonial) for estimating glu-
cose. The data was analyzed for change in glucose levels
in CNX-010-49 treated animals when compared with
HFD control.
Measurement of thermogenesis
For the cold exposure experiment, mice were housed in-
dividually and transferred to a cold environment with an
ambient temperature of 4°C. Body temperature was
assessed at the end of treatment period using a rectal
probe. Temperature was measured for every 15 min for
60–75 min and animals were then brought to room
temperature.
Estimation of liver TG
Liver TG was extracted according to Folch’s method.
The TG from liver homogenate was extracted with
chloroform: methanol (2:1) mixture, the organic layer
dried in a speed vac, re-suspended in isopropyl alcohol
and liver TG content was analyzed by using TG estima-
tion kit (Diagnostic systems, Germany).
Adipose tissue collection, immunofluorescence and image
analysis
Subcutaneous adipose tissue was removed and was fixed
in 10% buffered neutral formalin. It was then embedded
in paraffin, sectioned and stained. All adipose sections
were viewed at 40X magnification, and images were cap-
tured using Zeiss microscope connected via camera to a
computer (progres® capture pro 2.1 camera). Adipocytes
size measurement was performed using a computer-
assisted image analysis progres® capture pro software.
From each animal 10 images were measured. The area of
each adipocyte was measured by tracing the cell boundary
on the images captured. All adipocytes that had complete
cell boundary were measured. Data obtained after meas-
urement were averaged to individual animal and later
group mean and SEM were calculated.
For PRDM16 and UCP1 immuno staining, subcutane-
ous adipose sections were de-paraffinized and blocked in
1% BSA in PBS for 30 min at RT and incubated with
PRDM16 (ProSci, USA) or UCP1(Abcam, USA) primary
antibodies for 90 min at RT, followed by washing with
PBS. Sections were then incubated with secondary anti-
body (goat anti-rabbit Alexa Fluor 555 secondary anti-
body, Molecular Probes, Invitrogen) for 30 min at RT and
mounted using fluromount. Localization of PRDM16 and
UCP1 were assessed and the images were captured at 40X
magnification.Assessment of JNK and eIF2α phosphorylation
At the end of treatment period, 10 mg of muscle (soleus)
and subcutaneous adipose tissues were collected from
each animal in respective groups. Lysates were prepared
by homogenization and 50 μg lysate from each group
was subjected to SDS-PAGE, transferred onto nitrocellu-
lose membranes and probed with antibodies against
phospho-JNK, phospho-eIF2α, total JNK and Actin (Cell
signaling, USA) and developed by enhanced chemilu-
minescence (West Pico, Thermo Scientific, USA).
Estimation of serum biomarkers
Serum was collected at the end of the study and ELISA
(Enzyme Linked Immunosorbent Assay) was performed
as per the kit protocol to measure changes in leptin
(R&D system), PAI-1 (Invitrogen), Fetuin-A (Uscn Life
Science Inc) and IL-6 (R&D systems) levels in the
serum.
Statistical analysis
Prism 5.01 software (GraphPad Software, San Diego CA)
was used for statistical analysis. All the values are
expressed as Mean ± SEM and ‘n’ indicates the number
of animals in each group. When only two groups were
analyzed, statistical comparison was conducted by One-
way ANOVA followed by Dunnett’s test. Repeated meas-
ure based parameters (such as weekly fasting glucose,
serum triglycerides and body weight) were analyzed
using two-way ANOVA for repeated measures followed
by Bonferroni correction (with time and diet/inhibitor
treatment as factors). Statistical details (p-value, F, and
degree of freedom (Df)) are provided in the figure leg-
ends along with the results of the two-way ANOVA test-
ing. P < 0.05 was considered statistically significant.
Results
CNX-010-49 is a highly potent, selective inhibitor and has
a good pharmacodynamic activity
CNX-010-49 is a highly potent 11β-HSD1 inhibitor to-
wards both human and mouse isoforms with an IC50 of
6 nM and 64 nM respectively (Figure 1A & B) as estab-
lished from cells over expressing human 11β-HSD1 in
CHO-K1 cell and fully differentiated mouse C2C12 myo-
tubes respectively. IC50 for CNX-010-49 in primary
human mature adipocytes is 13 nM (Figure 1C). CNX-
010-49 inhibits reductase activity more than dehydrogen-
ase activity (>100X, Figure 1D). CNX-010-49 is highly se-
lective inhibitor with no inhibition up to 100 μM towards
11β-HSD2, 17β-HSD1 and 17β-HSD3 (Figure 1E, F & G).
In a single dose pharmacodynamic activity evaluation in
Swiss albino mice, oral administration of CNX-010-49 at
30 mg/kg inhibited 11β-HSD1 activity by 58% and 24% at
1 h and 7 h respectively in liver. In adipose, the inhibition
was 41% at 1 h and continued to be same till 7 h. In
Figure 1 Potency and selectivity of CNX-010-49. Inhibition curve with increasing concentrations of CNX-010-49 for reductase activity in CHOK1
cells stably expressing human 11β-HSD1 (A), Mouse C2C12 cells (B), fully differentiated human adipocytes (C), both reductase and dehydrogenase
activity with recombinant human 11β-HSD1 protein (D) as mentioned in the materials and methods. Selectivity of CNX-010-49 (100 μM) against
HSD related enzymes were evaluated in CHOK1 cells transiently over expressing human 11βHSD2 and 17β HSD3 respectively (E & G) and T47D
cells for 17βHSD1 (F). Data are means of three individual experiments with standard deviations (n = 6).
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At end of 24 h, there was no inhibition of 11β-HSD1
observed (data not shown). However there was no inhib-
ition observed in brain (Table 1).CNX-010-49 decreases liver gluconeogenic activity in
primary cultures of mouse hepatocytes and hence has a
potential to control fasting glucose
In the presence of gluconeogenic substrates (lactate and
pyruvate) along with signaling molecules (forskolin and
glucocorticoids), mouse hepatocytes showed a significant
increase in hepatic glucose release along with increase in
mRNA expression of both G6PC (glucose-6-phosphat-
ase, catalytic subunit) and PEPCK (phosphoenolpyruvate
carboxykinase) (5 and 9 fold increase respectively against
control cells) which are the key mediators of hepatic glu-
cose production. Inhibition of 11β-HSD1 by 1 μM of
CNX-010-49 significantly reduced hepatic glucose re-
lease by ~45% and mRNA expression of both G6PC andTable 1 Effect of CNX-010-49 on pharmacodynamic activity
Liver Sk
Time (h) 1 7 1
% inhibition with CNX-010-49 58 ± 2 24 ± 6 41 ± 4
After oral administration of CNX-010-49 at 30 mg/kg (single dose) to Swiss albino m
time points was measured in liver, muscle, adipose and brain tissues ex vivo as descPEPCK (40% and 70% respectively) indicating a potential
of CNX-010-49 to reduce fasting glucose (Figure 2A-C).CNX-010-49 increases muscle glucose oxidation, reduces
muscle proteolysis and increases mitochondrial biogenesis
In C2C12 myotubes, the presence of excess free fatty
acids, inflammatory cytokines and cortisone (in vitro dis-
ease mimicking condition); PDK4 (pyruvate dehydrogen-
ase kinase 4) mRNA expression was increased by more
than 4 fold as compared to vehicle control. Inhibition of
11β-HSD1 by CNX-010-49 reduced PDK4 expression by
40% (Figure 3A). Under the similar condition, we ob-
served around 2 fold increase in mRNA expression of
TRIM63 (tripartite motif containing 63; an E3 ubiquitin-
protein ligase which is known to enhance muscle prote-
olysis) as compared to vehicle control. Treatment with
CNX-010-49 reduced the expression by 30% (Figure 3B).
Mitochondrial copy number was decreased by ~75%
under disease mimicking condition compared to vehicleeletal muscle Adipose Brain
7 1 7 1 7
44 ± 5 38 ± 7 42 ± 5 0 0
ice (n = 4 per time point), pharmacodynamic activity of CNX-010-49 at different
ribed in Methods.
Figure 2 Effect of CNX-010-49 on liver gluconeogenesis in primary mouse hepatocytes. Mouse primary hepatocytes were treated with
glucose free media containing LPCF (5 mM Lactate, 5 mM Pyruvate, 1 μM cortisone, 10 μM of forskolin) with or without 1 μM of CNX-010-49 for
18 h. Post 18 h, glucose released in the media (A) and mRNA expression gluconeogenic markers G6PC and PEPCK (B & C) were measured as
mentioned in Methods. All the values are expressed as Mean ± SEM. Statistical comparison was conducted by One-way ANOVA followed by
Dunnett’s test (n = 6) (*P < 0.05, **P < 0.01 and ***P < 0.001).
Figure 3 Effect of CNX-010-49 on muscle glucose oxidation, proteolysis and mitochondrial biogenesis. C2C12 myotubes were treated
with GPCI (25 mM Glucose, 500 μM Palmitate, 1 μM of Cortisone, 10 ng/ml of each inflammatory cytokines (TNFa, IL1 β and IFNγ)) for 18 h with
or without 1 μM of CNX-010-49. Post 18 h, mRNA expression of PDK4 and TRIM63 (A & B) and mitochondrial gene ND1 (C) were measured as
mentioned in Methods. All the values are expressed as Mean ± SEM. Statistical comparison was conducted by One-way ANOVA followed by
Dunnett’s test (n = 6) (*P < 0.05, **P < 0.01 and ***P < 0.001).
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stored the mitochondrial number (Figure 3C).
CNX-010-49 inhibits both adipocytes differentiation,
lipolysis and hypertrophy
Conversion of inactive cortisone to active cortisol by
11β-HSD1 favors adipogenesis. CNX-010-49 treatment
reduced the differentiation/adipogenesis capacity by 34%
as measured by accumulation of triglycerides in adipo-
cytes as well as by oil red O staining (Figure 4A & B).
Both cortisone and isoproterenol stimulated lipolysis by 2
fold in mature 3T3-L1 adipocytes as measured by the re-
lease of glycerol in the culture medium. CNX-010-49
treatment reduced adipocytes lipolysis by 25% (Figure 4C).
Excess metabolic overload and inflammation mediated
hypertrophy of adipocytes as measured by enhanced tri-
glyceride accumulation, was reduced by 35% with CNX-
010-49 treatment (Figure 4D).
CNX-010-49 reduces fasting blood glucose in DIO mice
Compared to the lean control animals the HFD control
animals exhibited a significant increase in fasting glucose
(136 ± 6 vs. 200 ± 8 mg/dl; P < 0.001) during the entire
study period, indicating development of insulin resistance
and hyperglycemia (Figure 5A). In CNX-010-49 treated
animals, fasting glucose started decreasing from week 5 ofFigure 4 Effect of CNX-010-49 on adipocytes differentiation, hypertro
into mature adipocytes using complete differentiating media (CDM) in the pr
of adipocytes differentiation was assessed by measuring triglyceride levels (A)
were treated with 1 μM isoproterenol and 100 nM cortisone with or witho
media was measured (C). For inhibition of adipose hypertrophy, mature a
1 μM cortisone, 10 ng/ml of inflammatory cytokines (TNFa, IL1 β, IFNγ)) fo
accumulation was measured (D). All the values are expressed as Mean ± SEM
Dunnett’s test (n = 6) (*P < 0.05, **P < 0.01 and ***P < 0.001).treatment and by the end of treatment period reached a
significant 15% reduction (170 ± 6 vs 200 ± 5 mg/dl; P <
0.01) when compared with the HFD control mice.
We evaluated the gluconeogenic state of liver before
terminations of the study by performing a pyruvate tol-
erance test where animals were challenged with gluco-
neogenic substrate pyruvate and glucose levels in serum
was measured. Compared to lean control animals, HFD
animals showed an increase in serum glucose AUC
(20736 ± 1013 vs 26511 ± 2057) upon pyruvate challenge.
When compared with HFD control animals, CNX-01-49
treatment resulted in significant decrease in glucose
AUC (26511 ± 2057 vs 22775 ± 97) amounting to a ~15%
suggesting decreased gluconeogenesis (Figure 5B).
The HFD control animals showed an ~25% and ~50%
increase in fasting glycerol and free fatty acid levels re-
spectively when compared to lean control animals. CNX-
010-49 treated animals showed ~18% and 20% (P < 0.05)
decrease in fasting glycerol and free fatty acids respectively
(Figure 5C & D). This indicates that treatment with CNX-
010-49 modulates adipocytes physiology and reduces sup-
ply of pro-gluconeogenic substrates to the liver.
CNX-010-49 improves glucose tolerance in DIO mice
To examine whether glucose intolerance in HFD mice
was improved by the CNX-010-49 treatment, an oralphy and lipolysis. Mouse 3T3-L1 preadipocytes were differentiated
esence and absence of 1 μM of CNX-010-49. The extent of inhibition
and Oil red O staining (B). For inhibition of lipolysis, mature adipocytes
ut 1 μM of CNX-010-49 for 18 h. Post 18 h, glycerol released into the
dipocytes were treated with GPCI (25 mM glucose, 500 μM palmitate,
r 48 h with or without 1 μM of CNX-010-49. Post 48 h, triglyceride
. Statistical comparison was conducted by One-way ANOVA followed by
Figure 5 Effect of CNX-010-49 on fasting glucose in DIO mice of HFD. Fasting Glucose levels (A) were monitored weekly. To measure the
gluconeogenic state of liver, pyruvate tolerance test (B) was performed as described in the Methods. At the end of the treatment period, serum
glycerol (C) and free fatty acids (D) were measured as described in the Methods. Data in all panels are mean ± SEM (n = 8 mice/group). Statistical
comparison was conducted by One-way ANOVA followed by Dunnett’s test or repeated measures ANOVA followed by Bonferroni correction (A & B)
(n = 8 mice/group). Two-way repeated measures ANOVA indicated that CNX-010-49 significantly reduced the fasting glucose (p = 0.01; F = 5.08;
Df = 22) (# - significance of HFD control against lean control, *- significance of CNX-010-49 treatment against HFD control) (*P < 0.05, **P < 0.01
and ***P < 0.001).
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treatment. Upon oral glucose challenge, a significant in-
crease in the glucose excursion in HFD mice were ob-
served when compared to lean control (AUC of 57376 ±
1382 in HFD control vs 33803 ± 1919 in lean control; P <
0.001). However CNX-010-49 treatment showed ~13%
decrease in glucose levels (49680 ± 734 in treatment vs
57376 ± 1382 in HFD control; P < 0.05) indicating the po-
tential of CNX-010-49 to reduce post prandial hypergly-
cemia (Figure 6B).
CNX-010-49 reduces hyper insulinemia and improves
peripheral insulin sensitivity
In comparison with the lean control animals, HFD control
animals showed significant increase in fasting insulin
levels (0.59 ± 0.07 vs 1.94 ± 0.29 ng/ml; P < 0.001). Treat-
ment with CNX-010-49 significantly lowered plasma insu-
lin levels by ~40% (0.89 ± 0.11 vs 1.94 ± 0.29 ng/ml; P <
0.05) when compared with the hyperinsulinemic HFD
animals (Figure 6A). A similar trend was observed with
fed insulin. Along with reduced insulin levels, insulin
sensitivity was significantly improved in CNX-010-49
treated animals as evident from improved insulin tol-
erance test, reduced skeletal muscle phospho-JNK and
reduced subcutaneous adipose phospho-eIF2α levels(Figure 6C, D & E). Also we observed a significant
decrease in mRNA expressions of PDK4 and TRIM63
in muscle tissue of CNX-010-49 treated animals indi-
cating a possible improvement in glucose oxidation
(Figure 6F & G).
CNX-010-49 improves lipid profile in DIO mice
The effect of treatment on circulating TG levels is repre-
sented in Figure 7A.
In HFD control animals, the TG was increased by ~1.7
fold (210 ± 8 mg/dl; P < 0.001) when compared to lean
control (128 ± 8 mg/dl) during the study period. On the
other hand, the HFD fed animals treated with CNX-010-
49 showed ~20% reduction in TG levels (165 ± 9 mg/dl;
P < 0.001) when compared to HFD control. The decrease
in plasma TG upon CNX-010-49 treatment was ob-
served from week 1 and was maintained throughout the
study period. Also CNX-010-49 treatment has shown a
non-significant reduction in the liver TG levels as com-
pared to HFD control (Figure 7B).
We analyzed expression of fatty acid transporter CD36
and PPARα which is involved in fat oxidation in liver tis-
sue. As expected expression of CD36 increased by ~1.5
fold and a significant decrease in PPARα in HFD animals
as compared to lean control indicating increased fat
Figure 6 Effect of CNX-010-49 on insulin sensitivity, hyperinsulinemia and glucose clearance in DIO mice on HFD. At the end of the
treatment period, fasting and fed insulin levels (A) and OGTT was performed (B) by oral administration of glucose (2 g/kg); plasma glucose was
measured and AUC was calculated. Data in all panels are mean ± SEM (n = 8/group). At the end of the treatment, adipose and muscle tissue
samples were collected from Lean control (1), HFD Control (2) and CNX-010-49 treated animals (3) and subjected to Western blots for p-JNK/total
JNK (C) for muscle and p-EIF2α/Actin (D) for adipose. The blots are representative date from five animals from each group. ITT (E) was performed
in mice to determine the effect of CNX-010-49 on glucose clearance as mentioned in the Methods. mRNA expression levels of muscle PDK4 and
TRIM63 (F & G) were measured as mentioned in Methods. Statistical comparison between control was conducted by One-way ANOVA followed
by Dunnett’s test (n = 8 mice/group) (# - significance of HFD control against lean control, *- significance of CNX-010-49 treatment against HFD
control) (*P < 0.05, **P < 0.01 and ***P < 0.001).
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with CNX-010-49 showed a decrease in CD36 and in-
creased PPARα expression indicating a decreased fat up-
take and improved fat oxidation in liver as evident from
decreased liver and serum TG levels (Figure 7C & D).
CNX-010-49 has a potential to improve thermogenesis
and reduce body weight
In the lean control animals, a gradual increase in body
weight was observed during the 10 weeks study period
(25.6 g to 28.1 g). In contrast, body weight of HFD con-
trol animals showed a rapid increase and recorded ~18%
increase by end of the study (34.7 g to 41 g). Treatment
with CNX-010-49 prevented the weight gain by ~20%
(Figure 8A) without any change in the feed consumption(data not shown). We did not observe any significant in-
crease in body weight from week 1 rather CNX-010-49
treatment decreased the body weight gradually till week
5 and later maintained the same during complete treat-
ment period.
Histological analysis of white adipose tissue revealed
an increase in adipocytes size in HFD animals compared
to that of lean control. Treatment with CNX-010-49 re-
duced adipocytes size significantly by ~30% (Figure 8C
& D). Compared to HFD control animals, CNX-010-
49 treatment enhanced non-shivering thermogenesis
(Figure 8B). We observed a significant decrease in markers
of brown fat phenotype and thermogenesis; positive regula-
tory domain containing 16 (PRDM16) and uncoupling pro-
tein 1 (UCP1) in HFD control adipocytes. CNX-010-49
Figure 7 Effect of CNX-010-49 on lipid profile in DIO mice. Fasting serum TG levels (A) were monitored weekly. After the study termination,
liver TG (B) was analyzed. Data in all panels are mean ± SEM (n = 8 mice/group). mRNA expression levels of liver CD36 and PPARα (C & D) were
measured as mentioned in Methods. Statistical comparison was conducted by One-way ANOVA followed by Dunnett’s test or repeated measures
ANOVA followed by Bonferroni correction (A) (n = 8 mice/group). Two-way repeated measures ANOVA indicated that CNX-010-49 significantly
reduced the Fasting serum TG (p = 0.001; F = 1.865; Df = 20). (# - significance of HFD control against lean control, *- significance of CNX-010-49
treatment against HFD control) (*P < 0.05, **P < 0.01 and ***P < 0.001).
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pression thus shown a potential to enhance brown fat
phenotype and thermogenesis (Figure 8C).
Serum leptin levels were elevated in HFD control ani-
mals compared to lean control (43 ng/ml vs 1.24 ng/ml).
Treatment with CNX-010-49 reduced serum leptin levels
significantly by ~50% (22 ng/ml vs 43 ng/ml) (Figure 8E)
in comparison with the HFD control animals.CNX-010-49 has a potential reduce markers associated
with cardio vascular risks
Serum IL6 and PAI-1 levels (markers that are involved
in stress and cardio protection) in HFD control animals
were elevated significantly by 3 fold (161 pg/ml vs
50 pg/ml) and 3.5 fold (375 ng/ml vs 94 ng/ml) respect-
ively compared to lean controls. Also we observed a non-
significant decrease (~30%) in serum Fetuin-A levels in
HFD control animals compared to lean controls. Treat-
ment with CNX-010-49 decreased serum IL6 and PAI-1
levels significantly by ~75% (34 pg/ml vs 161 pg/ml)
and ~60% (148 ng/ml vs 375 ng/ml) in comparison with
HFD control animals. CNX-010-49 treatment increased
serum Fetuin levels as compared to HFD control (3.2 ng/ml
vs 1.2 ng/ml) (Figure 9A-C).Discussion
It is evident from multiple studies that glucocorticoids
excess plays an important role in the development of
metabolic syndrome, in particular T2DM [13]. Also it is
confirmed from many recent studies that tissue specific
glucocorticoids are involved in obesity and insulin resist-
ance against the circulatory glucocorticoids [35-37].
The effect seen in these studies is an evidence to
strengthen the understanding that tissue specific gluco-
corticoids play a major role in controlling metabolic syn-
drome. The pathology observed was not restricted to a
particular tissue rather from multiple tissues. The thera-
peutic potential will be appreciated when we restrict/re-
duce the tissue level cortisol, an active glucocorticoid in
multiple tissues.
In the present study, we have used a highly potent and
selective 11β-HSD1 inhibitor CNX-010-49 to study the
multiple aspects of the metabolic dysregulations as seen
in the metabolic syndrome in DIO mice on HFD. CNX-
010-49 is an orally dosable small molecule inhibitor of
11β-HSD1 which has a half-life of 7 h. It has shown a
good tissue distribution and 11β-HSD1inhbition in mul-
tiple tissues like liver, skeletal muscle and adipose tissue.
We did not observe brain 11β-HSD1 inhibition with
CNX-010-49 indicating there is no safety concerns in
Figure 8 Effect of CNX-010-49 on thermogenesis and body weight in DIO mice. Body weight was measured weekly (A). Non-shivering
thermogenesis was measured as described in the methods (B). Immunohistochemistry of PRDM16 and UCP1 (C) in subcutaneous adipose tissue
sections was performed as mentioned in the Methods. Subcutaneous adipocytes size (D) and serum leptin (E) levels were measured at the end
of treatment. Statistical comparison was conducted by One-way ANOVA followed by Dunnett’s test or repeated measures ANOVA followed by
Bonferroni correction (A) (n = 8 mice/group). Two-way repeated measures ANOVA indicated that CNX-010-49 significantly reduced body weight
(p = 0.001; F = 14.02; Df = 22). (# - significance of HFD control against lean control, *- significance of CNX-010-49 treatment against HFD control)
(*P < 0.05, **P < 0.01 and ***P < 0.001).
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activation [38]. Since several previous studies from both
T2DM humans and rodents have demonstrated elevated
tissue specific glucocorticoids [13,18-20], we did not
measure the tissue cortisol levels in our study.
Gluconeogenesis is one of the basic features of hepato-
cytes. Abnormal gluconeogenesis will lead to both fast-
ing and non-fasting glucose release in patients with type
2 diabetes. It is well established that 11β-HSD1 controls
key gluconeogenic genes PEPCK and G6PC expression
[39,40]. Our data clearly demonstrate that inhibition of
hepatic 11β-HSD1 by CNX-010-49 suppress hepatic glu-
cose output significantly along with reduced expression
of PEPCK and G6PC in cultured mouse hepatocytes.
DIO mice have shown a significant increase in fasting
glucose which was inhibited by treatment with CNX-
010-49. When challenged with pyruvate, CNX-010-49
treated animals had shown a reduction in glucose levels
indicating reduced gluconeogenic state of liver. These
data from both in vitro and in vivo clearly demonstrate
the role of 11β-HSD1 in hyperglycemia and inhibition
can give a potential benefit in controlling both fasting
and non-fasting hyperglycemia.
Glucocorticoid excess is known to induce insulin re-
sistance in skeletal muscle. This has a significant effect
on the glucose clearance in the periphery. It has beenshown that activity and expression of 11β-HSD1 in skel-
etal muscle has a significant impact on muscle insulin
resistance [23]. Also recent studies have shown that insu-
lin resistance can accelerate muscle protein degradation
by activating ubiquitin-proteasome system [41]. Glucocor-
ticoids are known to increase PDK4 [42,43] and TRIM63
(an E3 ubiquitin protein ligase also known as MuRF1) in
skeletal muscle cells [44]. Treatment with CNX-010-49 re-
duced hyperinsulinemia (both fasting and fed plasma insu-
lin levels) and improved peripheral insulin sensitivity as
evident from improved insulin tolerance test which was
further supported by reduced glucose intolerance. This
improvement in insulin sensitivity was further supported
by reduced phospho-JNK and phospho-eIF2α levels in
skeletal muscle and adipose tissues of treated animals re-
spectively. Treatment with CNX-010-49 reduced both
PDK4 and TRIM63 expression along with restoration of
mitochondrial copy number both in vitro and in vivo. In
adipose tissue, treatment with CNX-010-49 inhibited lip-
olysis. Collectively these data suggests an overall improve-
ment in the insulin sensitivity in the periphery.
Elevated tissue specific glucocorticoids are known to
cause dyslipidemia and insulin resistance. They increase
circulating triglyceride levels, hepatic de novo TAG
synthesis and storage [45,46]. Elevated CD36 expression
is known to increase hepatic triglyceride storage and
Figure 9 Effect of CNX-010-49 on markers associated with cardio vascular risks. At the end of the treatment, (A), PAI1 (B) and FetuinA
(C) levels in the serum were measured by ELISA. All the values are expressed as Mean ± SEM. Statistical comparison was conducted by One-way
ANOVA followed by Dunnett’s test (n = 8 mice/group) (*P < 0.05, **P < 0.01 and ***P < 0.001).
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HFD control mice. Treatment with CNX-010-49 re-
duced serum TG significantly indicating the role of 11β-
HSD1 in dyslipidemia. A non-significant reduction in
hepatic triglyceride content was observed with CNX-
010-49 treatment along with decreased CD36 expression
indicating that reduced serum TG is not because of ac-
cumulation in liver. We also observed a significant in-
crease in PPARα expression in liver indicating treatment
might have increased fatty acid oxidation. It is reported
in the literature that activation of PPARα reduces 11β-
HSD1 expression and activity in liver [48].
The role of 11β-HSD1 in obesity is well established
both by pharmacological interventions and also by knock-
out studies [28,30,32,49,50]. In agreement with the previ-
ous reports, we observed a significant decrease in body
weight with CNX-010-49 treatment without altering the
feed consumption rate (data not shown). CNX-010-49
treatment has reduced both adipocyte size and serum lep-
tin levels significantly. Glucocorticoids are known to
decrease non-shivering thermogenesis and favors lipid
storage in adipose tissue along with significant decrease in
UCP1 expression [51]. Recently it has been shown that
PRDM16 induces brown fat phenotype in white adipose
tissue [52]. Also it induces many other genes including
UCP1 which are directly involved in uncoupled cellular
respiration and energy expenditure [53]. Treatment withCNX-010-49 restores the expression of both PRDM16
and UCP1 in white adipose tissue. The relation between
glucocorticoids and PRDM16 is still needs to be
established.
Vascular calcification is known to be associated with
cardiovascular disease. Recently it has been shown that
serum Fetuin-A inhibits calcification [54,55]. Dexa-
methasone has been shown to suppress the expression
of genes that inhibit calcification [56]. Elevated plasma
levels of PAI-1 are known to associate with athero-
thrombosis and insulin resistance [57]. Glucocorticoids
are known to increase the production of PAI-1 from adi-
pose tissue [58]. Systemic chronic inflammation is a risk
factor for cardiovascular disease where IL-6 act as cen-
tral regulator [59]. CNX-010-49 treatment increased the
serum Fetuin-A levels and decreased PAI-1 and IL-6
levels significantly indicating a potential cardiovascular
benefit.Conclusions
In summary, CNX-010-49 is a selective and ‘pan’ tissue
acting, orally bioavailable 11β-HSD1 inhibitor. Pharma-
cological inhibition of 11β-HSD1 with CNX-010-49 has
normalized most of metabolic dysregulations like hyper-
glycemia, insulin resistance and dyslipidemia along with
body weight.
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covery program. Further characterization is necessary
before progressing to human studies.
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